AOSLO Imaging for the Study of Cellular Alterations in Retinal Neurodegeneration (NCT07725055) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
AOSLO Imaging for the Study of Cellular Alterations in Retinal Neurodegeneration
260 participantsStarted 2026-09
Plain-language summary
Primary objective:
\- Acquisition and analysis of images for non-medical purposes using the MONA IV system, an adaptive-optics-corrected scanning ophthalmoscope.
Secondary objectives:
* To measure the reproducibility of assessments;
* To evaluate the detection of progressive changes.
Who can participate
Age range
10 Years – 79 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
Patients:
* 100 subjects aged 10 to 79 years with a condition that may affect the inner retina (e.g., glaucoma, optic neuropathy, etc.)
* 100 subjects aged 10 to 80 years with a condition that may affect the outer retina (e.g., AMD, retinitis pigmentosa, etc.)
* Male or female
* Covered by health insurance
Healthy volunteers:
* 30 subjects aged over 50 and under 80
* 30 subjects aged over 18 and under 50
* Male or female
* Healthy subjects with no known condition that directly or indirectly affects the structure of the eye
* Covered by health insurance
Exclusion Criteria:
For all subjects:
* Inability to remain motionless on a standard ophthalmic chin rest. RETION\_Protocol\_v2.0 dated June 10, 2026\_IDRCB: 2026-A00324-47 Page 10 of 44
* Subjects taking medications or suffering from a medical condition that could interfere with the evaluations planned under the protocol;
* Participants allergic to tropicamide in cases where pupil dilation is required. ☞ Wearing glasses or contact lenses to correct a refractive error is not considered an exclusion criterion.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Proportion of images obtained with the MONA system deemed usable for the analysis of retinal microstructures.
Timeframe: 48 months
Trial details
NCT IDNCT07725055
SponsorCentre Hospitalier National d'Ophtalmologie des Quinze-Vingts